Literature DB >> 8373717

Metabolism of didanosine (ddI) by erythrocytes: pharmacokinetic implications.

M Barry, D Back, S Ormesher, N Beeching, F Nye.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8373717      PMCID： PMC1364562          DOI： 10.1111/j.1365-2125.1993.tb05899.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  5 in total

1.  Initial studies on the cellular pharmacology of 2',3'-dideoxyadenosine, an inhibitor of HTLV-III infectivity.

Authors:  D A Cooney; G Ahluwalia; H Mitsuya; A Fridland; M Johnson; Z Hao; M Dalal; J Balzarini; S Broder; D G Johns
Journal:  Biochem Pharmacol       Date:  1987-06-01       Impact factor: 5.858

2.  Pharmacokinetics of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in patients with severe human immunodeficiency virus infection.

Authors:  N R Hartman; R Yarchoan; J M Pluda; R V Thomas; K S Marczyk; S Broder; D G Johns
Journal:  Clin Pharmacol Ther       Date:  1990-05       Impact factor: 6.875

Review 3.  Chemotherapy of human immunodeficiency virus infections: current practice and future prospects.

Authors:  M S Hirsch
Journal:  J Infect Dis       Date:  1990-05       Impact factor: 5.226

4.  Altered erythrocyte nucleotide patterns are characteristic of inherited disorders of purine or pyrimidine metabolism.

Authors:  H A Simmonds; L D Fairbanks; G S Morris; D R Webster; E H Harley
Journal:  Clin Chim Acta       Date:  1988-02-15       Impact factor: 3.786

5.  Thermal inactivation of the acquired immunodeficiency syndrome virus, human T lymphotropic virus-III/lymphadenopathy-associated virus, with special reference to antihemophilic factor.

Authors:  J S McDougal; L S Martin; S P Cort; M Mozen; C M Heldebrant; B L Evatt
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808
  5 in total
  5 in total

1.  Relationship between didanosine exposure and surrogate marker response in human immunodeficiency virus-infected outpatients.

Authors:  J M Adams; M J Shelton; R G Hewitt; T H Grasela; M DeRemer; G D Morse
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

2.  Development of a Novel Maternal-Fetal Physiologically Based Pharmacokinetic Model I: Insights into Factors that Determine Fetal Drug Exposure through Simulations and Sensitivity Analyses.

Authors:  Zufei Zhang; Marjorie Z Imperial; Gabriela I Patilea-Vrana; Janak Wedagedera; Lu Gaohua; Jashvant D Unadkat
Journal:  Drug Metab Dispos       Date:  2017-06-06       Impact factor: 3.922

Review 3.  Concise overview of the clinical pharmacokinetics of dideoxynucleoside antiretroviral agents.

Authors:  D M Burger; P L Meenhorst; J H Beijnen
Journal:  Pharm World Sci       Date:  1995-03-24

4.  Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with the acquired immunodeficiency syndrome.

Authors:  M Barry; J L Howe; S Ormesher; D J Back; A M Breckenridge; C Bergin; F Mulcahy; N Beeching; F Nye
Journal:  Br J Clin Pharmacol       Date:  1994-05       Impact factor: 4.335

5.  Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in children with HIV infection.

Authors:  D Gibb; M Barry; S Ormesher; L Nokes; M Seefried; C Giaquinto; D Back
Journal:  Br J Clin Pharmacol       Date:  1995-05       Impact factor: 4.335
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.